Author: admin

  • How two early in career lawyers are shaping MinterEllison’s use of AI

    How two early in career lawyers are shaping MinterEllison’s use of AI

    When Kiara Morris, an early in career lawyer at MinterEllison, opens a draft of legal advice, she launches Microsoft Copilot alongside. With court dates approaching, she turns to the AI tool to anticipate potential questions from opposing counsel and uncover case examples relevant to her jurisdiction in Western Australia.

    “As a junior lawyer, there aren’t a lot of opportunities to get courtroom experience early on,” Morris explains. “With my first appearance coming up, Copilot has helped me think through the kinds of questions I might face. It’s been a huge boost to my confidence and how prepared I feel.”

    By mid-morning in MinterEllison’s Sydney office, Jett Potter is usually also working in Copilot, using agents he’s built to help shape briefing decks or review his work. The Lawyer, who is part of the firm’s AI advisory team, will drop an outline into his critique agent and ask it to improve the structure and tone, and pull any relevant research in so he can focus on the argument rather than formatting.

    “I rely on it for the majority of my day – more than I use Teams,” he explains. “I’ve created an agent that is designed to think like a top-tier consulting partner, pointing it to content that has been reviewed by Partners and has received positive feedback.

    “I can get to the final output faster because I’ve already incorporated multiple rounds of feedback using the agent before sharing it for review,” he said.

    Kiara and Jett are among the many young professionals who are using AI as a ‘rehearsal room’, a reviewer and more to accelerate their learning curves.

    Embracing high-value work with AI assistance

    Morris is using Microsoft Copilot’s Researcher Agent extensively in her role to speed up and deepen the research that she does as a junior lawyer.  

    “I work in the Infrastructure and Construction team, where I’m often getting my head around complex engineering terminology,” said Morris. “Researcher helps me quickly surface and contextualise technical concepts that aren’t necessarily legal but are important to understanding the client’s requirements.

    “It can be targeted at Western Australia specifically, ensuring I can deliver precise, context-appropriate information, making my research process much more thorough and efficient.”

    From there, she asks Copilot to probe her drafts from the client’s perspective to identify what’s missing, what questions could be asked and what she’ll need to defend. That way, she can pre-answer those questions before sending the draft up the chain.

    “When seniors ask, ‘Have you considered this approach?’, I can say yes, and justify why this is the best path forward. That builds their trust in me,” she says.  

    Potter, too, is using AI to accelerate his progression towards higher-value work. As part of the AI Advisory team, he uses his skills to build custom agents and design courses the firm can present to clients. He recently scoped a short AI training program with practice leads, grouping common questions into modules and pairing real scenarios with step-by-step prompts.

    That work brings him into partner and director discussions earlier, where he is invited to provide perspective on new initiatives and ideas for AI, as well as run demos.

    “There’s often a big shift from being a junior doing the administrative work to joining senior employees in thinking strategically about how we work with and what we offer clients. I feel like my early in career peers and I get to do more of that now because leaders are engaging with us for our AI skills.

    “We’ve just successfully sold our first AI training program to a client. It’s an idea that I originally proposed to our leadership and took the lead on drafting the supporting documents and prompt guide,” he says. “Using AI made the turnaround fast and didn’t impact my other priorities, while also giving me greater visibility with Partners.”

    What’s happening at MinterEllison mirrors a broader trend. In a recent data drop from  Microsoft, CTRL+Career, a survey of 500 early-career professionals across Australia and New Zealand found that 80 percent those surveyed feel their AI skills have given them more visibility at work compared to before they started using AI. Meanwhile, 83 percent also say their senior leaders actively seek input or ideas from them on how AI can be used at work.

    Improving career prospects by joining senior conversations

    Morris, Potter and other younger staff members are now being asked to contribute across the firm as its leaders seek to harness their practical understanding of AI.

    “I get opportunities to sit in high-level executive meetings where I’m two or three levels below the next person because they want our perspective on whether a process could be improved using AI,” says Potter.

    Morris says MinterEllison offices in Perth and across Australia have been sharing ways of developing day-to-day AI use, with her input. “I’ve had opportunities to share ideas and best practice for rolling out tools and client solutions with senior leadership, in a forum that wasn’t really possible before AI,” she says.

    However, despite the broad applications for this developing technology within their sector, both employees are conscious that human input will still be required to ensure all AI output meets the bar. Legal work, in particular, still demands a human at the centre of all client work.

    “We have professional obligations not to take information at face value,” says Morris. “Even if AI gives you a small extract from a case, you need to ensure the case as a whole is relevant – and this is the critical step to ensuring you actually learn the content that AI produces. If you’re just copying and pasting, it will get exposed later when seniors test your understanding.”

    Learning the content and not just using AI as information retrieval or shortcut remains top of mind for early in career professionals, with the CTRL+Career survey revealing that nearly half feel they don’t learn the content as well as they did before they started using AI. However, the majority (92 percent) feel confident in their ability to critically assess and challenge the AI-generated outputs – Signalling a need to ensure they are taught to use it to enhance critical thinking, not take away from it.

    While Potter also acknowledges the need for human checks and balances, he is ultimately convinced that AI literacy has become a non-negotiable for any aspiring employee, whether they are pursuing a career in law or another industry.

    “It’s a must. There’s this rumbling in our entire industry, with people asking, ‘Can AI replace my job?’ The way I think about it is that the person using AI will get your job,” he says. “So, you need to jump on the bandwagon. If nothing else, you need to understand how the technology works and how to get the most out of it. It’s not perfect; there are limitations, but you only know that by using it.”

    Continue Reading

  • When water runs out, some trees refuse to stop growing

    When water runs out, some trees refuse to stop growing

    When drought hits the African savanna, most trees shut down, hold back, and wait for rain. But one small, tough tree doesn’t follow the usual rules.

    The umbrella acacia, known for its flat-topped shape and resilience, does something unexpected…

    Continue Reading

  • Stem Cell Research Discovers Two Cells That Could Lead To Regenerating Teeth And Bone

    Stem Cell Research Discovers Two Cells That Could Lead To Regenerating Teeth And Bone

    Tooth loss and bone degeneration are problems that modern medicine still struggles to fix. Data from the National Bone Health Policy Institute shows that 10 million Americans over the age of 50 have been diagnosed with osteoporosis, and even more…

    Continue Reading

  • FIA FR/F4/GT World Cups – Great Macau graduates part one

    FIA FR/F4/GT World Cups – Great Macau graduates part one

    A long line of motor sport greats have taken on Macau’s iconic Circuito da Guia, venue for the upcoming FIA Formula Regional, Formula 4 and GT World Cups. Here’s a refresher of just some of them ahead of the 72nd…

    Continue Reading

  • Dua Lipa and Callum Turner Do Date Night Like the Biebers

    Dua Lipa and Callum Turner Do Date Night Like the Biebers

    If you were in New York City last night, you had a chance of spotting Dua Lipa and Callum Turner partaking in a romantic date night. The couple—who got engaged this summer—hit up a Saturday Night Live after-party together, where stars like…

    Continue Reading

  • Highlights from GCOS 2025 by Aaron Sverdlov

    Highlights from GCOS 2025 by Aaron Sverdlov

    Aaron Sverdlov/hmri.org.au

    The Global Cardio-Oncology Summit (GCOS) is an annual international conference that unites experts in cardiology and oncology to advance the rapidly…

    Continue Reading

  • Nationwide measles-rubella drive begins from Nov 17

    Nationwide measles-rubella drive begins from Nov 17





    Nationwide measles-rubella drive begins from Nov 17 – Daily Times
























    Continue Reading

  • Dr. Emrullah Yilmaz Joins Johnson and Johnson as Senior Medical Director

    Dr. Emrullah Yilmaz Joins Johnson and Johnson as Senior Medical Director

    Dr. Emrullah Yilmaz, MD, PhD, has stepped into a pivotal role as Senior Medical Director at Johnson & Johnson, a global leader in healthcare innovation. Announced through his professional network, Dr. Yilmaz shared his excitement for embarking on this new chapter, one that builds on a legacy of excellence in oncology, research, and collaborative medical leadership.

    Early Life and Academic Journey

    Originally from Turkey, Dr. Yilmaz pursued his formative medical education at Hacettepe University. His commitment to research and patient care was evident from the start, leading him to complete his MD and later earn his PhD focused on advanced oncology topics. His years at Hacettepe University laid the groundwork for his dedication to both scientific inquiry and the practical dimensions of clinical care.

    His academic journey continued through rigorous clinical training in both residency and fellowship programs, with posts at celebrated institutions in Turkey and the United States. A decisive move was his entry into cancer research as a postdoctoral scholar and then clinical fellow, honing his focus on head and neck oncology as well as precision medicine. These early years helped shape his philosophy of combining advanced therapeutics with compassionate patient-centered care.

    Career and Leadership Roles

    Before his recent appointment at Johnson & Johnson, Dr. Yilmaz held progressively senior roles in prestigious healthcare settings across the US. Notably, between 2016 and 2021, he served as Assistant Professor and Co-Leader of the Head & Neck Clinical Working Group at the University of New Mexico, where he developed new protocols for the management and clinical trial design in head and neck cancers.

    Joining Cleveland Clinic in 2021, Dr. Yilmaz became Head & Neck Medical Oncologist and then Director of Precision Oncology, further deepening his expertise in integrating genomics and individualized targeted therapy. In these positions, he mentored younger clinicians, influenced national cancer guidelines, and contributed meaningfully to multidisciplinary research teams.

    In 2024, his leadership roles expanded at Johnson & Johnson Innovative Medicine, first as Medical Director and subsequently as Senior Medical Director. Dr. Yilmaz now oversees medical strategy and clinical development at one of the world’s leading life sciences giants, where his focus is on translating scientific advances into effective therapies for patients globally.

    Research Contributions and Innovation

    Dr. Yilmaz is recognized for significant contributions in head and neck oncology, precision medicine, and clinical trials. His research has addressed the molecular basis of cancer, with emphasis on biomarker-driven therapy, improving outcomes in both common and rare tumor types.

    He has worked on projects that integrate large-scale genomic profiling into clinical workflows, enabling more personalized and adaptive approaches to cancer treatment. His published work covers topics such as therapeutic sequencing in head and neck cancers, real-world use of targeted drugs, and the application of novel immunotherapies.

    Peer-reviewed journal articles authored or co-authored by Dr. Yilmaz appear in publications such as the Journal of Clinical Oncology, CA: Cancer Journal for Clinicians, and Cancer Research. His leadership in multi-institutional studies and advisory roles for pharmaceutical innovation highlight a commitment to data-driven and evidence-based advancement in oncology.

    Recognition and Awards of Emrullah Yilmaz

    Dr. Yilmaz’s career trajectory is marked by multiple honors reflecting his dedication to clinical excellence and scientific advancement. He has received distinguished awards for his work in translational oncology and clinical trial innovation, although specific public awards are not overtly shared in social media profiles. His reputation among colleagues is evidenced by invitations to speak at international congresses and serve on expert panels within organizations such as the American Society of Clinical Oncology.

    A New Chapter at Johnson & Johnson

    Dr. Yilmaz’s recent announcement made via Linkedln reflects both a sense of accomplishment and forward-looking vision:

    “I’m happy to share that I’m starting a new position as Senior Medical Director at Johnson & Johnson!”

    In this capacity, Dr. Yilmaz will lead teams focused on the global development of novel cancer therapies, mentor clinical scientists, and support partnership building across research networks. His appointment affirms Johnson & Johnson’s ongoing commitment to advancing medical science through expert leadership and international collaboration.

    Looking Ahead

    With Dr. Emrullah Yilmaz’s appointment, Johnson & Johnson further strengthens its position as an industry leader in the creation and dissemination of life-saving therapies. Dr. Yilmaz’s unique blend of medical expertise, research rigor, and visionary leadership aligns perfectly with the company’s mission to improve health outcomes for patients worldwide.

    His journey—from a dedicated young clinician-researcher in Turkey to senior roles spanning top US academic medical centers, culminating in a key directorial position at Johnson & Johnson—serves as inspiration to the next generation of clinicians and scientists. Dr. Yilmaz continues to exemplify the ideals of innovation, patient-centered care, and global impact in medical oncology.

    Continue Reading

  • DevEx Resources And Two More Noteworthy Picks

    DevEx Resources And Two More Noteworthy Picks

    The Australian market is showing resilience, with shares moving towards a modest gain despite volatility in global indices. As investors navigate these shifting conditions, penny stocks remain an intriguing area of interest. Although the term may seem outdated, it still represents smaller or less-established companies that can offer potential value. By focusing on those with strong financials and growth potential, investors might uncover promising opportunities among these lesser-known stocks.

    Name

    Share Price

    Market Cap

    Financial Health Rating

    Alfabs Australia (ASX:AAL)

    A$0.49

    A$140.43M

    ★★★★★☆

    EZZ Life Science Holdings (ASX:EZZ)

    A$2.25

    A$106.14M

    ★★★★★★

    Dusk Group (ASX:DSK)

    A$0.895

    A$55.73M

    ★★★★★★

    IVE Group (ASX:IGL)

    A$2.79

    A$428.8M

    ★★★★★☆

    MotorCycle Holdings (ASX:MTO)

    A$3.77

    A$278.25M

    ★★★★★★

    Pureprofile (ASX:PPL)

    A$0.048

    A$56.15M

    ★★★★★★

    West African Resources (ASX:WAF)

    A$3.04

    A$3.47B

    ★★★★★★

    LaserBond (ASX:LBL)

    A$0.53

    A$62.59M

    ★★★★★★

    Service Stream (ASX:SSM)

    A$2.27

    A$1.39B

    ★★★★★★

    Fleetwood (ASX:FWD)

    A$2.95

    A$272.39M

    ★★★★★★

    Click here to see the full list of 418 stocks from our ASX Penny Stocks screener.

    Let’s review some notable picks from our screened stocks.

    Simply Wall St Financial Health Rating: ★★★★☆☆

    Overview: DevEx Resources Limited, along with its subsidiaries, focuses on the exploration and evaluation of mineral properties in Australia, with a market cap of A$61.84 million.

    Operations: The company’s revenue segment is derived from Exploration and Evaluation, amounting to A$0.36 million.

    Market Cap: A$61.84M

    DevEx Resources is a pre-revenue company with a market cap of A$61.84 million, focusing on mineral exploration in Australia. Despite having no debt and short-term assets of A$7.4 million exceeding both its short and long-term liabilities, the company faces financial challenges with less than a year of cash runway and ongoing unprofitability. Recent earnings reports show a net loss reduction to A$9.11 million for the year ended June 2025, yet auditors have expressed concerns about its ability to continue as a going concern. The management team is experienced but must navigate these financial hurdles carefully.

    ASX:DEV Financial Position Analysis as at Nov 2025

    Simply Wall St Financial Health Rating: ★★★★★★

    Overview: GR Engineering Services Limited offers engineering, process control, automation, and construction services to the mining and mineral processing industries globally, with a market cap of A$613.49 million.

    Continue Reading